Gentian Diagnostics ASA

Regulatory Filings • Mar 29, 2017

GENTIAN ENTERS LAST PHASE OF DEVELOPMENT WITH PLASMA CALPROTECTIN

GENTIAN ENTERS LAST PHASE OF DEVELOPMENT WITH PLASMA CALPROTECTIN

Moss, 29 March 2017

Gentian Diagnostics AS (OSE: GENT-ME) is pleased to announce that it

has achieved design verification on its product G-CAL (Gentian

Calprotectin Immunoassay), a novel test for diagnosing inflammation

in blood samples with automated analyzers.

G-CAL will now enter the validation phase, the very last step in

Gentian's development process. Commercial launch of G-CAL is

expected in 3Q/17.

For further information, please contact:

Bård Sundrehagen

CEO, Gentian Diagnostics AS

E-mail: Bard.sundrehagen@gentian.no

Cell Phone: +47 924 14 117

ABOUT GENTIAN DIAGNOSTICS AS

Gentian Diagnostics AS is a medical diagnostics company listed on

Merkur Market, Oslo Stock Exchange with the ticker "GENT-ME".

Gentian is headquartered in Moss, Norway, with a representative

office in China and distribution subsidiaries in Sweden and USA.

Gentian designs, develops and markets in vitro diagnostic reagents

(IVD) based on its proprietary Nanosense technology. The goal is to

offer efficient and accurate reagents for major clinical chemistry

platforms with a focus within the areas of kidney disease, cardiac

disease, inflammation and veterinary medicine. The Nanosense

technology will enable users to move assays from low volume

immunology platforms to fully automated, high throughput instruments

with shorter turnaround times, better workflow and improved cost

efficiency.